Slides
Page 1
© Copyright Diaceutics 2026 . You must seek permission to replicate any part of this presentation RYAN KEELING | CHIEF EXECUTIVE OFFICER | RYAN.KEELING@DIACEUTICS .COM NICK ROBERTS | CHIEF FINANCIAL OFFICER | NICK.ROBERTS@DIACEUTICS .COM
Page 2
DISCLAIMER AND FORWARD - LOOKING STATEMENTS Disclaimer : The information provided in this presentation is for the sole use of those attending the presentation This presentation has been prepared by Diaceutics the (“Company”) . “Presentation” means this document, any oral presentation, any question and answer session and any written or oral material discuss ed, presented or distributed during the meeting . This Presentation does not constitute or form part of any offer to sell or issue, or invitation to purchase or subscribe for, or any solicitation of any offer to purchase or subscribe for, any securities of the Company or any of its subsidiaries (together the “Group”) or in any other entity, nor shall this Presentation or any part of it, or the fact of its Presentation, form the basis of, or be relied on in connection with, any contract or investment activity nor does it constitute a recommendation regarding the securities of the Group . Past performance, including the price at which the Company’s securities have been bought or sold in the past and the past yield on the Company’s securities, cannot be relied on as a guide to future performance . Nothing herein should be construed as financial, legal, tax, accounting, actuarial or other specialist advice and persons needing advice should consult an independent financial advisor or independent legal counsel . Neither this Presentation nor any information contained in this Presentation should be transmitted into, distributed in or otherwise made available in whole or in part by the recipients of the Presentation to any other person in any jurisdiction which prohibits or restricts the same except in compliance with or as permitted by law or regulation . Recipients of this Presentation are required to inform themselves of and comply with all restrictions or prohibitions in such jurisdictions . Accordingly, by requesting to receive and reviewing this document you represent that you are able to receive this document without contravention of any legal or regulatory restrictions applicable to you . The information in this Presentation is confidential and proprietary to and is being submitted to you solely for your confidential use and with the explicit understanding that, without the prior written permission of the Company you will not release or discuss this Presentation, its existence, any of the information contained herein, or make any reproduction of or use this Presentation for any purpose . No responsibility is accepted by and, to the fullest extent permitted by law, the Company, the Group, their affiliates, advisors and their respective directors, officers, partners, representatives, employees and agents expressly disclaim any and all liability, whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, as to the accuracy, fairness, reliability or completeness of the information contained herein or discuss ed verbally or as to the reasonableness of any assumptions on which any of the same is based or the use of any of the same or for any errors, omissions or misstatements in or from this Presentation . No representations or warranties, express or implied, are given by the Company, the Group, their affiliates and advisors and their respective directors, officers, partners, representatives, employees and agents as to the accuracy, reliability or completeness of this Presentation or any other written or oral information which has been or may be made available . Accordingly, no such person will be liable for any direct, indirect or consequential loss or damage suffered by any person resulting from the use of the information contained herein, or for any opinions expressed by any such person, or any errors, omissions or misstatements made by any of them . No duty of care is owed or will be deemed to be owed to any person in relation to the Presentation . No reliance whatsoever may be placed on the Presentation for any purpose . By accepting this Presentation, you agree to use and maintain any such information in accordance with your contractual obligations and applicable laws, including all applicable securities laws . The information contained in this Presentation has not been independently verified . This Presentation is intended only for communications with investors . Forward - Looking Statements : This Presentation may contain forward - looking statements containing the words "expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward - looking statements . The forward - looking statements in this communication are based on numerous assumptions and the Company present and future business strategies and the environment in which the Company expects to operate in the future . Forward - looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results , performance or achievements to be materially different from those expressed or implied by such forward - looking statements, and actual results could differ materially from those currently anticipated due to a number of risks and uncertainties . These statements are not guarantees of future performance or the ability to identify and consummate investments . Many of these risks and uncertainties relate to factors that are beyond each of the Company ability to control or estimate precisely, such as future market conditions , the course of the COVID - 19 pandemic, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Company ability to obtain financing, changes in the political, social and regulatory framework in which the Company operates or in economic, technological or consumer trends or conditions . This Presentation does not constitute an invitation or inducement to engage in investment activity . Similarly, this Presentation does not constitute or form part of any offer or invitation to sell or issue or any solicitation of any offer to purchase or subscribe for any securities of the Company in any jurisdiction, nor shall it (nor any part of it) or the fact of its distribution form the basis of, or be relied upon in connection with, or act as any inducement to enter into, any contract or investment decision in relation thereto . The delivery of this Presentation shall not give rise to any implication that there have been no changes to the information and opinions contained in this Presentation since the time specified . None of the Company, the Group, their affiliates and advisors and their respective directors, officers, partners, representatives, employees and agents, undertakes to publicly update or revise any such information or opinions, including without limitation, any forward - looking statement or any other statements contained in this Presentation, whether as a result of new information, future events or otherwise . In giving this Presentation none of the Company, the Group, their affiliates and advisors and their respective directors, officers, partners, representatives, employees and agents, undertakes any obligation to provide the recipient with access to any additional information or to update any additional information or to correct any inaccuracies in any such information which may become apparent . Certain industry and market data contained in this Presentation has been obtained from third party sources . Third party industry publications , studies and surveys generally state that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data . While the Company believes that each of these publications , studies or surveys has been prepared by a reputable source, the Company has not independently verified the data contained therein accordingly the Company, the Group, their affiliates and advisors and their respective directors, officers, partners, representatives, employees and agents, expressly disclaim, to the maximum extent permitted by law and regulation, any and all responsibility or liability as to the accuracy, completeness or reasonableness of the information provided . In addition, certain of the industry, scientific and market data contained in this Presentation comes from the Company’s own internal case studies, research and estimates based on the knowledge and experience of the Company’s management in the market in which it operates . While the Company believes that such research, estimates and results from its case studies are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness unless otherwise stated and are subject to change without notice . By attending the Presentation you agree to be bound by the limitations above . 2
Page 3
H1 2026 STRATEGIC AND COMMERCIAL HIGHLIGHTS The Board remains confident in delivering against its 2026 expectations. + Diaceutics continues to work with 18 of the top 20 global pharma companies, supporting 55 customers across 103 therapeutic brands. + Precision For All proposition expands the Company’s market opportunity from traditional precision medicine into the broader universe of diagnostic - driven therapies. + Signal ARR has grown by 46% in the first 6 months of 2026 and is used across 55 brands (Jun - 25: 36) + Continued investment in DXRX, proprietary data assets and AI - enabled analytics strengthened the Group’s intelligence and engagement platform. + Repositioning launched to market, presenting Diaceutics as the intelligence and engagement company unlocking the full potential of diagnostic - driven therapies. + Commercial and delivery model redesigned to support scale, clearer accountability, improved customer delivery and greater operating leverage. + Launch of dedicated Growth function to identify and develop opportunities outside the routes to market served by our core pharmaceutical commercial organization. 3
Page 4
H1 2026: OPERATIONAL HIGHLIGHTS GLOBAL PHARMA 18 of 20 H1 2025: 18 of 20 AVE. NUMBER OF PEOPLE 205 H1 2025: 206 BRANDS 103 H1 2025: 89 ENTERPRISE CUSTOMERS 10 H1 2025: 8 RELAY (PMX) CUSTOMERS 2 H1 2025: 1 CUSTOMERS 55 H1 2025: 50 RELAY (PMX) ARR £4.3m H1 2025: £1.4m Expanding our addressable markets and capturing more value INCREASE ADOPTION IN PRECISION MEDICINE MARKET Actively upsell solutions to new and existing brands within the core precision medicine market and extend coverage of services throughout the commercialization lifecycle. Ultimately, look to embed Relay ( PMx ) with every customer brand. EXTEND OUR MARKET REACH INTO PRECISION FOR ALL Increase current market reach from precision medicine market into Precision For All – any therapies with diagnostically driven patient pathways. TAM $1.0bn 400 brands Progressing to Plan 73 brands up from 68 TAM $0.4bn 700 brands Launched in 2025 30 brands up from 21 MARKET OPPORTUNITY CURRENT PROGRESS 4
Page 5
H1 2026 FINANCIAL HIGHLIGHTS *EBITDA is earnings before interest, tax, depreciation and amortization. Adjusted EBITDA removes share - based payment charges and once - off exceptional items. **Annual Recurring Revenue (ARR) is the value of recurring subscription revenue at a specific point in time that is expected to be recognized from contracts over the next twelve months. + Revenue increased 20% to £17.5 million, or 22% on a constant currency basis. + ARR increased 79% to £29.4 million, with NRR of 149% and gross ARR churn reduced to 6%. + Order book increased 38% to £43.7 million, with £15.7 million contracted for H2 2026 delivery. + Gross profit increased 23% to £14.9 million, with gross margin expanding to 85%. + Adjusted EBITDA increased to £1.1 million, demonstrating emerging operating leverage. + Positive free cash flow of £ 0.7 million; £8.1 million of cash and no debt – fully funded to deliver the organic growth strategy 5
Page 6
STRONG ARR GROWTH DRIVES H2 REVENUE & PROFIT VISIBILITY REVENUE £17.5m +20% / vs £14.6m ARR £29.4m +79% / vs £16.4m RECURRING REVENUE 61% +6 pp% / vs 55% ADJUSTED EBITDA £1.1m +£1.0 / vs £0.1m CASH / NET CASH £8.1m vs £10.4m ORDER BOOK £43.7m +38% / vs £31.7m REVENUE GROWTH ADJ EBITDA PROFITABILITY Reported +20% | Constant currency +22% | 3 - yr CAGR 21% 9.9 12.3 14.6 17.5 13.8 19.8 23.9 29.3 0.0 5.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0 45.0 50.0 2023 2024 2025 2026 £ millions Revenue H1 (A) Revenue H2 (A) Revenue H2 (F) - 0.1 - 0.9 0.1 1.1 2.9 5.1 7.5 9.1 -2.0 0.0 2.0 4.0 6.0 8.0 10.0 12.0 2023 2024 2025 2026 £ millions Adj EBITDA Adj EBITDA H1 (A) Adj EBITDA H2 (A) Adj EBITDA H2 (F) Adj EBITDA £1.1m | Loss Before Tax £4.0m | Free Cash Flow £0.7m 107% visibility on achieving FY 2026 median analyst consensus revenue estimates (F) Denotes consensus estimates based on published analyst research. The Company neither endorses nor adopts these estimates, and they should not b e regarded as Company guidance. 42:58 38:62 38:62 12% 13% 20% 6
Page 7
INCREASING REVENUE QUALITY & VISIBILITY REVENUE MIX ARR MOVEMENT TOTAL ORDER BOOK £43.7m H2 CONTRACTED £15.7m GROSS CHURN (Lost customers) - 6% NET REVENUE RETENTION 149% 6.8 8.8 12.5 5.5 5.7 4.9 0.0 2.0 4.0 6.0 8.0 10.0 12.0 14.0 16.0 18.0 20.0 H1 2024 H1 2025 H1 2026 £ millions Recurring Non-recurring +31 pp / vs 118% +13 pp / vs - 19% +74% / vs £9.0m +38% / vs £31.7m 16.4 13.3 - 1.0 0.6 29.4 Jun - 25 Customer expansion Lost customers fx Jun - 26 £ millions 0.0 5.0 10.0 15.0 20.0 25.0 30.0 35.0 Recurring revenue increases 6 pp to 61% as ARR grows 79% and total order book grows 38% +79% Customer retention, brand growth and upsell of ARR products are driving quality and visibility 7
Page 8
OPERATING LEVERAGE DRIVING PROFIT & CASH GROWTH ADJUSTED EBITDA BRIDGE CASH FLOW BRIDGE GROSS MARGIN 85% | vs 83% ADJ. EBITDA MARGIN 6.0% | vs 0.4% FREE CASH FLOW +£0.7m | vs - £2.4m 7.3 0.3 1.2 1.9 - 2.4 - 0.2 8.1 £ millions 0.0 2.0 4.0 6.0 8.0 10.0 12.0 FCF £0.7m Priorities: Selected investments to facilitate organic growth, scale operating activities and costs, improve working capital cas h conversion Investing in marketing and sales enablement whilst realising scale in people costs 0.1 2.4 0.4 - 0.8 - 0.9 - 0.1 1.1 £ millions 0.0 0.5 1.0 1.5 2.0 2.5 3.0 8
Page 9
DIACEUTICS BUSINESS MODEL We deliver solutions that help life sciences companies: Find the patient. Remove the barrier. Activate the physician. Improve therapy adoption. Measure the outcome. WHY IT SCALES Each new lab or hospital in the network improves coverage and solution quality Reveal data asset can power multiple subscription products and service layers Agentic AI increases speed, insight generation and operating leverage Recurring subscriptions improve revenue visibility, resilience and compounding growth Customer expansion creates both topline upside and a more efficient delivery model 01 PARTNER NETWORK 670 labs and hospitals contribute de - identified testing data and real - world diagnostic signals 02 DATA + AGENTIC AI MODEL Diaceutics normalizes fragmented data, infers clinical intent and enriches it with agentic AI to create higher - value intelligence 03 SUBSCRIPTION SOLUTIONS Insights are productized into subscription offerings and services, including Signal, Physician Engage and activation support 04 PHARMA ACTIONABILITY Commercial, medical and market access teams use these products to identify opportunity, prioritize action and improve execution 05 CUSTOMER VALUE CREATION More patients on therapy, stronger topline growth and lower cost - to - serve through a more effective model 9
Page 10
DIACEUTICS MOAT PARTNER NETWORK DIAGNOSTIC DATA CLINICAL INTELLIGENCE ACTIVATION CUSTOMER OUTCOMES DEEPER EMBEDDING 01 02 03 04 05 06 PARTNER NETWORK 670 labs & hospitals in the partner network + Long - tail access beyond the major reference - lab networks + It takes years to onboard a new lab data partner + Testing and laboratory data reveal what claims alone cannot + Curated into a proprietary data asset built for clinical intent and actionability PROPRIETARY DIAGNOSTIC DATA Differentiated diagnostic signals across real patient journeys CLINICAL INTENT & ACTIONABILITY From a diagnostic event to the next best commercial action EMBEDDED SUBSCRIPTION PRODUCTS Signal • Physician Engage • Relay + Subscription products embed insight into pharma workflows + Relay deepens enterprise, multi - year customer relationships + Faster insight generation and disease - model deployment + Supports scale without linear growth in manual effort AGENTIC AI SCALE ENGINE AI agents enrich, interpret and operationalise fragmented data CUSTOMER DISTRIBUTION ADVANTAGE 18 of top 20 pharma • 55 customers • 103 brands + Customer distribution and breadth reinforce the moat + More customers and brands create more product learning and deeper reach + Testing behavior helps identify clinical intent + Integrated into the physician office workflow 10
Page 11
WHAT IS PRECISION FOR ALL? PRECISION MEDICINE Tailors treatment using molecular, genetic or biomarker information to identify the right patient for the right therapy. PRECISION FOR ALL Builds on precision medicine and extends the same logic to the broader universe of diagnosis - enabled therapies PRECISION FOR ALL CREATES VALUE Whenever diagnostic testing, patient identification, disease stratification or practice - gap detection changes commercial success. Precision Medicine is the foundation. Precision For All is the broader commercial category. PRECISION MEDICINE High - value, biomarker - defined subset ~250 PM brands (illustrative) PRECISION FOR ALL Broader diagnosis - enabled therapy universe ~1,100 diagnosis - enabled therapies (illustrative) Companion diagnostic / biomarker - defined therapies Non - oncology diagnosis - enabled therapies Diagnosis & treatment decision gaps Severity / phenotype stratification Early identification & risk prediction Precision For All ~1,100 diagnosis - enabled therapies (illustrative) PRECISION MEDICINE ~250 PM brands (illustrative) 11
Page 12
PRODUCT LINEUP DXRX connects diagnostic intelligence with scientific engagement to turn insight into coordinated commercial action 12
Page 13
DIAGNOSTIC - DRIVEN COMMERCIALIZATION DXRX targeted commercialization increases biopharma commercial prescriptions and reduces commercialization budgets between 12 - 41%. Diaceutics is actively supporting two Relay (formerly PMx ) commercialization engagements for US biopharma clients. IMPACT Targeted commercialization is designed for the US healthcare market to deliver measurable outcomes by improving alignment to bes t - practice testing, supporting more informed physician decision - making and increasing the likelihood that eligible patients reach appropria te therapy. 78% of signaled & engaged HCPs have gone on to treat 100% Increase in best practice testing 82% of HCPS reported increased understanding of the disease 13
Page 14
SIGNAL: CASE STUDY How real - time diagnostic signals drove measurable commercial impact Each additional patient was worth approximately $220k in average client revenue. 2.0x Immediate uplift in patient starts 18 months Sustained improvement $350 ROI per $1 invested 2.0x 1.0x 0 Patient starts (relative to baseline) Week 27: DXRX Signal activated Baseline period Weeks 1-26 Activation Week 27 Sustained uplift Weeks 28+ (18 months) THE CHALLENGE A pharma client needed to identify patients with a specific lung cancer mutation so it could target the right physicians and sales interactions more effectively. THE INTERVENTION (activated week 27) DXRX Signal was activated in Week 27, enabling real - time identification of eligible patients and more precise commercial outreach. THE IMPACT Patient starts doubled immediately at activation and the uplift was sustained over the following 18 months. Patient starts doubled following activation, and the uplift was sustained over the following 18 months. 14
Page 15
PRECISION FOR ALL Growth driven by customer success SIGNIFICANT & GROWING MARKET OPPORTUNITY • Biopharma are rapidly shifting to diagnosis - enabled healthcare to target better patient care, capture lost revenue and increase profitability STRONG COMPETITIVE MOAT • Comprehensive US lab partner network • Proprietary multimodal healthcare data asset • AI - enabled and scalable DXRX platform COMPELLING VALUE PROPOSITION HIGH - QUALITY REVENUE MODEL PROVEN EXECUTION • High growth ARR business • Increasing multi - year revenue visibility • High gross margin and profitable • Strong balance sheet and fully funded to support growth • 18 of top 20 pharma • 103 therapeutic brands • Two Relay ( PMx ) commercialization engagements • Proven commercial execution • Founder led management • High ROI - $100 of additional customer revenue for every $1 spent on DXRX • Blue - chip customers • More patients identified • Better testing & therapy adoption 15
Page 16
TEAM & CONTACTS Ryan Keeling Chief Executive Officer Nick Roberts Chief Financial Officer DXRX LN / DXRX.L i nvestorrelations@diaceutics.com Hayley Palmer Canaccord Genuity hpalmer@cgf.com Julie Simmonds Panmure Liberum julie.simmonds@panmureliberum.com Chris Glasper Singer Capital Markets chris.glasper@singercm.com Christian Glennie Stifel christian.glennie@stifel.com Natalia Webster RBC Capital Markets natalia.webster@rbccm.com 16
Page 17
PROFIT AND LOSS (P&L) AND BALANCE SHEET STATEMENT OF CHANGES IN EQUITY (SOCIE) AND CASH FLOW
Page 18
P&L AND BALANCE SHEET 30 - Jun - 26 30 - Jun - 25 31 - Dec - 25 (Unaudited) (Unaudited) (Audited) £000’s £000’s £000’s ASSETS Non - current assets Intangible assets 15,746 15,362 16,080 Right of use assets 2,027 1,090 1,108 Property, plant and equipment 493 621 556 Deferred tax asset 4,482 2,886 2,902 22,748 19,959 20,646 Current assets Trade and other receivables 20,944 13,512 21,256 Income tax receivable 359 568 762 Cash and cash equivalents 8,102 10,384 7,344 29,405 24,464 29,362 TOTAL ASSETS 52,153 44,423 50,008 EQUITY AND LIABILITIES Equity Equity share capital 170 170 170 Treasury shares - 312 - 312 - 312 Translation reserve - 843 - 1,266 - 980 Profit and loss account 39,735 38,649 41,602 TOTAL EQUITY 38,750 37,241 40,480 Non - current liabilities Lease liability 1,818 905 882 Provision for dilapidations 74 93 95 1,892 998 977 Current liabilities Trade and other payables 11,184 5,951 8,254 Lease liability 276 229 270 Income tax payable 51 4 27 11,511 6,184 8,551 TOTAL LIABILITIES 13,403 7,182 9,528 TOTAL EQUITY AND LIABILITIES 52,153 44,423 50,008 Six months to Six months to Year ended 30 - Jun - 26 30 - Jun - 25 31 - Dec - 25 (Unaudited) (Unaudited) (Audited) £000’s £000’s £000’s Revenue 17,456 14,564 38,437 Cost of sales - 2,595 - 2,477 - 6,958 Gross profit 14,861 12,087 31,479 Administrative expenses - 18,941 - 15,435 - 31,691 Other operating income 64 169 255 Operating (loss)/profit - 4,016 - 3,179 43 Finance income 74 195 317 Finance costs - 26 - 29 - 58 (Loss)/profit before tax - 3,968 - 3,013 302 Income tax credit/(charge) 1,199 612 - 205 (Loss)/profit for the financial period - 2,769 - 2,401 97 18
Page 19
SOCIE AND CASH FLOW Equity share capital Treasury shares Translation reserve Profit and loss account Total equity £000’s £000’s £000’s £000’s £000’s At 1 January 2025 170 - 312 - 626 40,625 39,857 Loss for the period - - - - 2,401 - 2,401 Other comprehensive loss - - - 640 - - 640 Share based payments - - - 425 425 At 30 June 2025 (unaudited) 170 - 312 - 1,266 38,649 37,241 Profit for the period - - - 2,498 2,498 Other comprehensive income - - 286 - 286 Share based payments - - - 490 490 Deferred Tax Credit - - - - 35 - 35 At 31 December 2025 (audited) 170 - 312 - 980 41,602 40,480 At 1 January 2026 170 - 312 - 980 41,602 40,480 Loss for the period - - - - 2,769 - 2,769 Other comprehensive income - - 137 - 137 Share based payments - - - 940 940 Deferred Tax Credit taken directly to equity - - - - 38 - 38 At 30 June 2026 (unaudited) 170 - 312 - 843 39,735 38,750 Six months to Six months to Year ended 30 - Jun - 26 30 - Jun - 25 31 - Dec - 25 (Unaudited) (Unaudited) (Audited) £000’s £000’s £000’s Loss/(profit) before tax - 3,968 - 3,013 302 Adjustments to reconcile loss before tax to net cash flows from operating activities Net finance income - 48 - 164 - 259 Amortisation of intangible assets 3,118 2,494 5,355 Research and development tax credits - - - 62 Depreciation of RoU asset and PPE 240 207 457 Decrease/(increase) in trade and other receivables 1,178 3,863 - 5,151 Increase/(decrease) in trade and other payables 1,917 - 3,139 643 Share based payments 924 425 915 Cash generated from operations 3,361 673 2,200 Tax paid - 12 - 68 - 1,021 Net cash inflow from operating activities 3,349 605 1,179 Investing activities Purchase of intangible assets and PPE - 2,446 - 2,822 - 6,448 Finance interest received 74 195 317 Net cash outflow from investing activities - 2,372 - 2,627 - 6,131 Financing activities Leasehold repayments - 179 - 141 - 333 Net cash outflow from financing activities - 179 - 141 - 333 Net increase/(decrease) in cash and cash equivalents 798 - 2,163 - 5,285 Net foreign exchange movements - 40 - 197 - 115 Opening cash and cash equivalents 7,344 12,744 12,744 Closing cash and cash equivalents 8,102 10,384 7,344 19